Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.40 +0.40%

+$0.09 today

Market cap
$2.95B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 2.37M

Average 1.84M

DNLI Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Denali Therapeutics Inc.NASDAQ: DNLI

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity falls 18.7% from a year ago

Total equity stood at $835.18M at the end of Q2 FY2026, down 18.7% from a year earlier and down 9.8% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.

Context

  • Total equity amounted to 72.1% of total assets at the end of Q2 FY2026, down 15.9 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -18.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$835.18M-9.8% QoQ
Last fiscal yearDec 2025
$1.01B-17.6% YoY
Year agoJun 2025
$1.03B-18.7% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.7%——
1 year-17.6%——
3-year CAGR-0.9%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
1.01B USD
Year-over-year change
-17.6%
4-year CAGR
+1.3%

Total Equity vs competitors

How DNLI compares with its peers on the latest reported figures

  • DNLI's Jun 2026 total equity of $835.18M is the 3rd highest of the 11 companies compared; the peer median is $232.16M.
  • Its year-over-year change of -18.7% is the 7th highest of 11, against a peer median of +47.0%.
  • Total equity amounts to 72.1% of total assets for DNLI, versus a peer median of 75.8%.
DNLI Competitors Peer median
Total Equity for DNLI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NBIXNeurocrine Biosciences, Inc.Sep 2026$3.88B +29.1%+24.0%68.9%
PRAXPraxis Precision Medicines, Inc.Sep 2026$1.26B +266.7%+126.0%96.0%
DNLIDenali Therapeutics Inc.Jun 2026$835.18M -18.7%-0.9%72.1%
AMLXAmylyx Pharmaceuticals, Inc.Sep 2026$753.74M +127.0%-3.6%95.8%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$471.51M +65.0%+191.8%94.8%
IONSIonis Pharmaceuticals, Inc.Sep 2026$393.64M -36.3%-5.1%13.5%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$70.68M -69.0%—45.9%
PMNProMIS Neurosciences, Inc.Jun 2026$49.4M +13012.1%—87.1%
CGTXCognition Therapeutics, Inc.Mar 2026$29.91M +143.8%-5.2%82.8%
BHVNBiohaven Ltd.Jun 2026$12.22M -90.9%-54.1%3.3%
ALECAlector, Inc.Mar 2026$10.38M -89.0%-47.7%4.3%
Peer median (excluding DNLI) $232.16M+47.0%-4.4%75.8%

Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents293.48M218.04M127.11M174.96M205.33M
Short-term Investments571.93M1.12B907.41M657.37M662.55M
Net Receivables1.23M9.28M3.42M2.17M2.18M
Inventory00000
Other Current Assets000030.6M
Total Current Assets897.23M1.37B1.06B864.44M900.66M
Property, Plant & Equipment (Net)69.61M74.52M71.64M125.63M119.94M
Goodwill00000
Intangible Assets00000
Long-term Investments425.45M1.5M0359.37M98.32M
Tax Assets00000
Other Non-current Assets11.87M11.9M18.14M24.74M25.94M
Total Non-current Assets506.93M87.92M89.78M509.74M244.2M
Total Assets1.4B1.46B1.15B1.37B1.14B
Account Payables4.78M2.79M9.48M11.14M3.33M
Short-term Debt00000
Tax Payables00000
Deferred Revenue320.3M290.05M000
Other Current Liabilities19.01M17.09M21.59M38.86M53.28M
Total Current Liabilities378.25M363.92M77.98M102.21M98.35M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)4.69M479K000
Other Non-current Liabilities379K379K05.62M5.53M
Total Non-current Liabilities63.63M53.89M44.98M42.29M32.74M
Total Liabilities441.87M417.81M122.96M144.5M131.09M
Common Stock1.55M1.69M1.71M1.77M1.89M
Retained Earnings(645M)(970.99M)(1.12B)(1.54B)(2.05B)
Accumulated OCI(2.5M)(6.89M)643K2.02M682K
Other Stockholders Equity00000
Minority Interest00000
Total Equity962.29M1.04B1.03B1.23B1.01B
Total Debt64.01M60.35M52.24M48.71M36.76M
Net Debt(229.47M)(157.69M)(74.87M)(126.25M)(168.57M)

Denali Therapeutics Inc.

NASDAQ:DNLI

Intrinsic Alpha fair value

Locked

Current Price

$18.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.